Get the Stockscreener App
25.20
1.06%
-0.2689
Cue Health Inc stock is traded at $25.20, with a volume of 3,747.
It is down -1.06% in the last 24 hours and up +57,976% over the past month.
Cue Health Inc., a healthcare technology company, designs and develops diagnostic platform and products for diagnostic tests for public sectors, healthcare providers, large enterprises, and individual consumers. The company offers Cue Integrated Care platform that provides real-time access to the consumers and enterprises; and Cue Health Monitoring System that designs to perform in vitro diagnostic tests. Its Cue Health Monitoring System consists of cue reader, cue cartridge, and cue wand. The company also offers Cue Data and Innovation Layer that provides a secure environment for users to access current and historical health data; Cue Virtual Care Delivery apps; and Cue Ecosystem Integrations and apps. In addition, it provides Cue COVID-19 Test Kit to for ribonucleic acid of SARS-CoV-2, the virus that causes COVID-19. The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. The company was incorporated in 2010 and is headquartered in San Diego, California.
See More
Previous Close:
$25.47
Open:
$25.31
24h Volume:
3,747
Relative Volume:
5.71
Market Cap:
$6.90M
Revenue:
$64.22M
Net Income/Loss:
$-373.46M
P/E Ratio:
-10.33
EPS:
-2.44
Net Cash Flow:
$-157.61M
1W Performance:
+57,976%
1M Performance:
+57,976%
6M Performance:
+57,976%
1Y Performance:
+57,976%
1-Day Range:
$25.20
$25.31
1-Week Range:
$24.88
$25.47
52-Week Range:
$24.88
$25.47
Cue Health Inc Stock (HLTH) Company Profile
Name
Cue Health Inc
Sector
Industry
Phone
858-412-8151
Address
4980 Carroll Canyon Road, Suite 100, San Diego
Compare HLTH vs VEEV, BTSG, HQY, TEM, TXG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HLTH
Cue Health Inc
|
25.20 | 6.90M | 64.22M | -373.46M | -157.61M | -2.44 |
VEEV
Veeva Systems Inc
|
186.24 | 30.25B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
72.91 | 14.31B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
94.64 | 7.91B | 1.34B | 230.70M | 440.96M | 2.6695 |
TEM
Tempus Ai Inc
|
42.69 | 7.69B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
46.27 | 5.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
Cue Health Inc Stock (HLTH) Latest News
Tema's AI ETF Targets Drug Discovery, Diagnostics and Robotics - Stock Titan
TUBI APPOINTS SHANNON OLIVAS AS HEAD OF COMMUNICATIONS AND PUBLICITY - Tubi
Needham reiterates Hold on Conmed stock amid sale exploration - Investing.com
Cue Biopharma names Dominic Borie as chief medical officer - Investing.com
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development - Yahoo Finance
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH - RTTNews
Cue Biopharma (Nasdaq: CUE) secures $50M private placement and grants over 1M RSUs - Stock Titan
Cue: The Market Is Paying $86M For A Drug It Doesn't Own (NASDAQ:CUE) - Seeking Alpha
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Biotech firm Cue Biopharma lines up $50M to push its immune disorder drugs - Stock Titan
Cue Health Inc. Actuals & Estimates (OTC:HLTHQ) - TradingView
Cue Biopharma Inc (CUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why Temasek’s CFO is moving into a new power role - Fortune
Conmed Names John Gallagher as New Chief Financial Officer - The Globe and Mail
Cue Biopharma (NASDAQ: CUE) registers 551,724 pre-funded-warrant shares for resale - Stock Titan
CONMED Appoints John E. Gallagher as New Chief Financial Officer, Effective July 2026 - Minichart
Conmed names John Gallagher as CFO effective July 15 By Investing.com - Investing.com Australia
Conmed names John Gallagher as CFO effective July 15 - Investing.com
CONMED (NYSE: CNMD) hires John Gallagher as CFO with equity-heavy pay - Stock Titan
CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer - Business Wire
Cue Biopharma Inc (CUE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cue Biopharma Inc (CUE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cue Biopharma Inc (CUE) Institutional Confidence - TradingKey
Cue Biopharma, Inc. (CUE) Latest Stock News & Headlines - Yahoo Finance
Cue Biopharma adds two directors as four board members resign - Investing.com UK
CUE - Finviz
Apple’s Top Executive Uses a Whoop — What That Says About the Company’s $100 Billion Apple Watch Problem - Yahoo Finance
CUE Stock Price, Quote & Chart | CUE BIOPHARMA INC (NASDAQ:CUE) - ChartMill
Cue Biopharma CEO to present at Jefferies healthcare conference in NYC - Stock Titan
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference - Yahoo Finance
Why Is Cue Health Inc. (HLTHQ) Stock Down Today? - Meyka
Cue Biopharma reports Q1 loss, secures $30M financing - Investing.com UK
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments - The Manila Times
Cue Biopharma (CUE) boosts Q1 revenue, raises $30M and trims net loss - Stock Titan
[10-Q] Cue Biopharma, Inc. Quarterly Earnings Report - Stock Titan
New Cue Biopharma CEO lines up $30M to advance allergy, autoimmune drugs - Stock Titan
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
New Cue Biopharma CEO gets 655,074-share option and 327,537 stock units - Stock Titan
CUE stock jumps over 100% after hours — what’s driving the rally? - MSN
Cue Biopharma Secures Exclusive License for Dual-Mechanism Anti-IgE Antibody, Expanding Pipeline for Allergic and Autoimmune Diseases - Minichart
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Cue Biopharma stock surges over 65% overnight: Why is it moving? - MSN
Cue Biopharma raises $30M in private placement - MSN
Cue Biopharma jumps as investors react to Ascendant-221 licensing deal and fresh financing news | CUE Stock News - Quiver Quantitative
Cue pays $15M for allergy drug, targets food allergy trial - Stock Titan
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody - The Manila Times
Two board hires back Made Scientific’s move toward commercial cell therapy - Stock Titan
Cue Biopharma licenses anti-IgE antibody for allergic diseases - Investing.com
Harrow announces leadership changes, Andrew Boll to serve as President and CFO - MSN
Cue Biopharma’s Nasdaq Move Signals Strategic Share Realignment - Kalkine Media
12 Health Care Stocks Moving In Tuesday's Intraday SessionFirefly Neuroscience (NASDAQ:AIFF), AIxCrypt - Benzinga
Cue Health Inc Stock (HLTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.99%
2.12%
Cap:
|
Volume (24h):